114737-99-4

Basic information

• Product Name: Cyclohexanol, 3-(phenylmethoxy)-, cis-
• CAS NO: 114737-99-4
• Molecular Formula: C13H18O2
• Molecular Weight: 206.285
• Mol File: 114737-99-4.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: Cyclohexanol, 3-(phenylmethoxy)-, cis-(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclohexanol, 3-(phenylmethoxy)-, cis-(114737-99-4)
• EPA Substance Registry System: Cyclohexanol, 3-(phenylmethoxy)-, cis-(114737-99-4)

Safety Data

• Hazardous Substances Data: 114737-99-4(Hazardous Substances Data)

Upstream product

• 32700-48-4 [(cyclohex-2-en-1-yloxy)methyl]benzene 
• 84029-18-5 (1RS,3RS,6SR)-3-(benzyloxy)-7-oxabicyclo[4.1.0]heptane 
• 127383-49-7 c-5-(benzyloxy)-t-2-chloro-r-1-cyclohexanol 
• 84029-20-9 racemic cis-1-benzyloxy-7-oxabicyclo[4.1.0]heptane 
• 100611-66-3 ((cyclohex-3-enyloxy)methyl)benzene 
• 822-67-3 Cyclohex-2-enol 
• 504-01-8 cyclohexane-1,3-diol 
• 100-39-0 benzyl bromide 
• 823-18-7 cis-1,3-cyclohexanediol 
• 1192-78-5 2,3-epoxycyclohexanol 
• 127383-48-6 c-4-(benzyloxy)-t-2-chloro-r-1-cyclohexanol 

Downstream Products

• 123990-98-7 3-benzyloxycyclohexan-1-one 
• 755030-78-5 C₁₇H₂₂O₅ 
• 1361392-04-2 4-(3-(benzyloxy)cyclohexyloxy)-3,5-difluoro-4'-(methylsulfonyl)biphenyl 
• 1361392-05-3 3-(3,5-difluoro-4'-(methylsulfonyl)biphenyl-4-yloxy)cyclohexanol 
• 1361392-07-5 3-(3,5-difluoro-4'-(methylsulfonyl)biphenyl-4-yloxy)cyclohexyl 3-methyl butanoate 
• 755030-76-3 C₁₈H₂₆O₃ 
• 1361392-02-0 2-(3-(benzyloxy)cyclohexyloxy)-5-bromo-1,3-difluorobenzene 

Relevant articles and documents

Exploiting η5- to η3-Indenyl Ring Slippage to Access a Directed Reaction: Ether-Directed, Rhodium-Catalyzed Olefin Hydroboration

-

CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS

This invention relates to a series of substituted cyclohexane containing analogues which are agonists of GPR119 intended to treat metabolic diseases mediated by GPR119 including Type I & II diabetes mellitus. Diabetes mellitus is an ever-increasing threat to human health causing various complications (blindness, kidney failure, neuropathy, heart attack, stroke, etc.). Recently it was found that activation of GPR119 which is highly expressed in pancreatic beta cells causes glucose dependent insulin secretion and GLP-1 release. Many pharmaceuticals are currently developing GPR119 agonists and herein we disclose alternative GPR119 agonists. Our invention describes GPR119 agonists having structural Formula (I), pharmaceutically acceptable salt or solvate of Formula (I), isomer or prodrug of Formula (I), and combination therapy of Formula (I) with other anti-diabetic drugs like DPP-IV inhibitors and/or insulin sensitizers.

Synthesis and catalytic activity of rhodium diene complexes bearing indenyl-type fullerene η5-ligand

Rhodium η5-complexes bearing an indenyl-type fullerene ligand, Rh[C60(PhCH2)2Ph](cod) (2), Rh[C60(PhCH2)2Ph](nbd) (3) and Rh(C70Ph3)(cod) (4), have been synthesized from the corresponding fullerene tri-adducts in 93-96% yields. X-ray crystallographic analysis of 4 indicated that the structure of 4 is similar to that of Rh(Ind)(cod). The rhodium complex 2 catalyzes alkyne trimerization reactions and hydroboration reactions.